BACKGROUND: Metabolic syndrome (MetS) is associated with cancer risk and increases the risk of Barrett esophagus, which is the precursor lesion of esophageal adenocarcinoma (EA), primarily in the absence of gastroesophageal reflux disease (GERD). However, to the authors' knowledge, little is known regarding whether MetS is associated with the risk of EA. METHODS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database, the authors evaluated whether MetS was associated with EA. A total of 3167 cases of EA were compared with individually matched population controls (5:1); a subset of 575 EA cases were able to be individually matched with 575 Barrett esophagus controls. MetS was defined using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes in the period 1 to 3 years before the diagnosis of EA or control selection. Unconditional logistic regression was used to estimate adjusted odds ratios and 95% confidence intervals. Potential effect modification by GERD symptoms and sex was examined in stratified models. RESULTS: EA was found to be significantly associated with MetS (odds ratio, 1.16; 95% confidence interval, 1.06-1.26) compared with population controls. In males, the association was restricted to those individuals without prior GERD; however, in females, MetS was found to be associated with EA regardless of GERD status. Effect modification by sex was observed (P for interaction 5 .01). MetS was not found to be associated with EA risk when compared with Barrett esophagus controls. CONCLUSIONS: In this older population, MetS was found to be associated with an increased risk of EA in males without GERD and females regardless of GERD status. Given the lack of an association when compared with Barrett esophagus controls, MetS may impact EA risk by primarily increasing the risk of the precursor lesion, Barrett esophagus. Cancer 2017;123:657-65.
INTRODUCTION
The incidence of esophageal adenocarcinoma (EA) has rapidly increased in the United States over the last 30 years. 1 EA is a lethal malignancy, with a majority of patients surviving <1 year. 2 This malignancy is believed to arise within Barrett esophagus (BE), a metaplasia caused by chronic exposure to gastroesophageal reflux. 3 Previous studies have demonstrated that obesity increases the risk of gastroesophageal reflux disease (GERD), 4, 5 although to the best of our knowledge the mechanisms by which obesity promotes the development of EA are not completely understood and are likely multifactorial. 6 Obesity, especially central adiposity, can increase the risk of GERD by amplifying intragastric pressure, 7 disrupting normal esophageal sphincter function, 8 and increasing the risk of hiatal hernia. 9 However, in addition to the impact of these "mechanical" sequelae of obesity, obesity may increase the risk of EA and BE through a route that is independent of GERD. One such mechanism may include promoting inflammation by secreting multiple proinflammatory cytokines (eg, tumor necrosis factor-a, interleukin 6 [IL-6], leptin, and adiponectin,). 10 A proxy for such obesogenic effects is metabolic syndrome (MetS), 11 which is defined as a constellation of metabolic disorders that include obesity, impaired fasting glucose, high blood pressure, and dyslipidemia. MetS has been associated with increased risks of cardiovascular disease, total mortality, 12 and various malignancies. 13, 14 In a prior study of Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we demonstrated that MetS was associated with an increased risk of BE, the precursor lesion of EA. However, the association was restricted to those individuals without a history of GERD. 15 We proposed that the direct, proinflammatory effects of GERD cause esophageal tissues to reach a saturated inflammatory state, in which the effects of MetS have little or no additional effect, thereby negating any observable association. Conversely, in those patients without symptomatic GERD, systemic inflammation conferred by MetS increases the risk of BE.
Although to our knowledge a few studies to date have demonstrated an association between BE and MetS, [15] [16] [17] [18] only a single study has evaluated MetS in relation to EA using multiple prospective cohorts, with the accrual of 114 cases of EA in total. 19 MetS was found to be associated with an increased risk of EA. Considering that obesity was the only metabolic factor found to be associated with EA, the authors concluded that the association was likely attributable to obesity increasing the propensity for GERD. However, given that MetS previously has been associated with BE in those without a history of GERD, evaluating MetS in relation to EA by reflux exposure is warranted. Furthermore, MetS could increase the risk of EA by increasing the risk of the precursor lesion, BE, or by increasing the risk of BE progression to cancer. Therefore, we assessed whether MetS, as a proxy of systemic inflammation, was associated with EA risk overall and in subgroups defined by GERD and sex in an analysis of the SEER-Medicare database.
MATERIALS AND METHODS

Data Source
For the current study, we used the SEER-Medicare database, which links cancer registry data from SEER and Medicare enrollment and health claims files. The population-based SEER registries collect demographic and clinical information for each patient living within defined geographic areas. The SEER areas included in the current study cover approximately 28% of the US population. The Medicare data, collected by the Centers for Medicare and Medicaid Services, include claims for each beneficiary with fee-for-service coverage, with information regarding all inpatient hospitalizations and outpatient and physician services. All files include dates of service and codes for diagnoses and procedures using the using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. The database is comprised of multiple files that were created during an electronic linkage of the SEER and Medicare data, as has been previously described. 20, 21 The SEERMedicare files were used to identify EA cases and 2 control groups: population controls (Medicare beneficiaries) and BE controls (described further below).
Study Population
We identified all individuals diagnosed with EA in the SEER-18 registries between 2003 and 2009 with ICD-9 codes 150.0 to 150.9 and International Classification of Diseases for Oncology (ICD-O) codes 8140 to 8575. Cases diagnosed at autopsy or by death certificate were excluded.
To ensure complete Medicare coverage for each individual, those not enrolled in Medicare Parts A and B continuously for at least 3 years before diagnosis/selection were excluded. We further excluded those individuals enrolled in Medicare before age 64.5 years, and those enrolled in a health maintenance organization. Given the inclusion criteria, EA cases and controls were aged 67.5 years at diagnosis/selection.
We selected 2 control groups from the 5% random sample of Medicare beneficiaries residing within SEER regions: population controls and BE controls based on incidence-density sampling with replacement between risk sets. Five population controls were selected for each EA case diagnosed between 2003 and 2009 based on age at the time of diagnosis (61 year), sex, race, and SEER registry. Population controls were those who had not received an EA diagnosis by July 1st of the calendar year of diagnosis of the corresponding case. Complete matching resulted in the inclusion of 3167 EA cases and 15,835 population controls.
To the extent possible, one BE control was selected for each EA case diagnosed between 2003 and 2009 using the same matching variables as the population controls. BE controls were defined as Medicare beneficiaries with a BE diagnosis made after July 1, 2003 through 2009. The BE diagnosis was captured by ICD-9-CM code 530.85, which is a code specific for BE that was introduced by the Centers for Medicare and Medicaid Services in 2003. In addition, we required the BE controls to have undergone an endoscopy (codes 43200, 43201-43205, 43215-43217, 43219, 43220, 43226-43228, 43231, 43232, 43234-43251, and 43255-43259) within the period 3 months prior to 1 month after the date of the BE diagnosis. BE controls identified with ICD-9-CM code 530.85 were excluded if they had received a prior diagnosis with ICD-9-CM code 530.2 (ulcer of the esophagus), which previously has been used for BE but is nonspecific. The Barrett control pool was limited by matching based on month and year of diagnosis and by SEER registry. Only a subset of EA cases could be matched with a BE control.
Original Article
Incomplete matching in the EA compared with the BE analysis resulted in the inclusion of 575 EA cases and 575 BE controls.
Definition of MetS and Covariate Selection
MetS was defined as suggested by the US National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III), 22 which requires the presence of at least 3 of the following conditions: elevated waist circumference/central obesity, elevated triglycerides, lowered highdensity lipoprotein cholesterol, high blood pressure, and elevated fasting glucose. There was no specific ICD-9-CM code for elevated waist circumference before 2001, and therefore we used an indication of obesity or morbid obesity as a proxy for this exposure. Reduced high-density lipoprotein cholesterol was not assessed due to the absence of a specific ICD-9-CM code for this condition. Type II diabetes diagnoses were included in the definition of elevated fasting glucose. This definition of MetS in studies of SEER-Medicare data has been used previously 15, 23 ; it includes the following ICD-9-CM codes: 278.0, 278.01, 278.00, V85.3, and V85. 4 24 We also included the following risk factors previously demonstrated to be associated with EA: tobacco smoking (yes/no), defined using codes for personal history of tobacco use, excessive use of tobacco products, and toxic effects of tobacco (codes V15.82, 305.1, and 989.84, respectively); and GERD symptoms (yes/no), defined using codes for gastroesophageal reflux, reflux esophagitis, esophagitis, or heartburn (codes 530.81, 530.11, 530.10, and 787.1, respectively). Risk factors, including metabolic factors, were identified between 1 and 3 years before either EA diagnosis or the index date for population controls. We excluded conditions documented within the year preceding the diagnosis date or the index date to reduce differential ascertainment bias that may result from increased medical encounters in the year before the cancer diagnosis.
Modified Charlson Comorbidity Index Score
We derived a comorbidity score for each individual based on the clinical comorbidity index 25 developed by Charlson et al, 26 updated by Deyo et al, 27 and expanded by Klabunde et al. 28 Briefly, our Charlson Comorbidity Index score was a weighted score based on inpatient and outpatient Medicare claims data during the exposure window of 3 years to 1 year before the date of the cancer diagnosis, BE diagnosis, or pseudodiagnosis. The Charlson Comorbidity Index weighted score was categorized into none (0), low (1), moderate (2), and high (3).
Statistical Analyses
To characterize the case and control groups, we calculated frequencies and percentages for categorical variables and the means and standard deviations for continuous variables. Assessed variables included age at the time of diagnosis or selection (continuous), sex, race (white, black, or other/unknown), SEER registry, Charlson Comorbidity Index score (categorical: 0, 1, 2, or 3), GERD (yes/no), type II diabetes, individual metabolic conditions (obesity, elevated fasting glucose, elevated blood pressure, or elevated triglycerides), and MetS. Unconditional logistic regression models were used to calculate adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) of associations between MetS exposures and EA. 29 The models included variables whose inclusion altered the log OR estimates for MetS by >10% (smoking), factors with a known or probable association with EA (GERD), and the matching variables (age, sex, race, and SEER registry). 30 Additional adjustment for the severity of comorbidities as captured by the Charlson Comorbidity Index score did not appear to change effect estimates and therefore were not included in the final adjusted models. We assessed effect modification by including an interaction term of GERD and MetS in adjusted logistic regression models and examining the Wald P value for interaction, as well as through analyses stratified by GERD and by sex because GERD may be associated with MetS [31] [32] [33] and sex plays pivotal roles in the development of MetS and EA. A 2-sided P value < .05 was considered to be statistically significant. All analyses were performed using Stata statistical software (version 13; StataCorp LP, College Station, Tex). Table 1 shows selected characteristics of the 2 case-control groups that were selected. The majority of EA cases diagnosed between 2003 and 2009 were white and male. The prevalence of smoking was higher in the EA cases (11.4%) compared with population controls (7.7%), but similar to that in BE controls (approximately 12% each). EA cases had a greater percentage of gastroesophageal reflux (26.1%) compared with population controls (18.0%), but less compared with BE controls (27.1% vs 38.8%, respectively). Table 3 summarizes the association between EA and MetS and individual conditions of MetS stratified by GERD status. In the no-GERD stratum, MetS was associated with an OR of 1.19 (95% CI, 1.08-1.32) when comparing EA cases with population controls (Table 3) . However, among patients with a history of GERD, no significant association between MetS and EA was observed (OR, 1.07; 95% CI, 0.90-1.27) and the Wald P value for interaction was not statistically significant (P interaction of GERD 5 .231). Additional stratification by sex provided tentative evidence of stronger associations in females (ORs of approximately 1.4) that, unlike the more attenuated results for males, did not appear to differ by GERD status (Table 4) . When stratified by sex alone, the association between MetS and EA appeared stronger in females (OR, 1.44; 95% CI, 1.20-1.73) than in males (OR, 1.09; 95% CI, 0.99-1.20) (P interaction 5 .011) ( Table 5) .
RESULTS
DISCUSSION
In this large population-based analysis, we found a positive association between MetS and the risk of EA when compared with population controls. This association appeared stronger in those individuals without a prior history of GERD, although this difference was not found to be statistically significant. There was tentative evidence that the overall association between MetS and EA was stronger in women than in men. There was no evidence of effect modification by GERD in women, but modest evidence was noted among men. There was no association noted between MetS and EA when compared with BE controls. To the best of our knowledge, the current study is the first population-based study to evaluate the association between MetS and EA risk in the United States.
MetS and GERD both represent proinflammatory states. Although local inflammation induced by reflux may be the dominant mechanism by which cytokines, reactive oxygen species, and other factors are released, leading to a proinflammatory and favorable tumor microenvironment, this does not preclude a role for systemic inflammation that may be captured by MetS. 6 The results of the current study suggest that in men, when direct inflammatory routes of association are not saturated by the inflammatory effects of GERD, an indirect proinflammatory state may contribute to risk of EA. To the best of our knowledge, why the association between MetS and EA may be stronger in women and may not differ by GERD is unknown. It is interesting to note that women presenting with GERD are more likely to have nonerosive disease (ie, reflux symptoms and a normal endoscopy), whereas men are more likely to have erosive esophagitis. 34, 35 This could be related to the observation that testosterone is positively associated with BE, 36 possibly due to the inhibition of reepithelization, [37] [38] [39] which could expand the interval for opportunistic metaplastic repopulation and subsequent malignancy. Alternatively, sex differences in antioxidative capacity 40 may equip women with a more favorable response to the direct, inflammatory effect of GERD, thereby enabling indirect, systemic inflammation to contribute to disease risk regardless of GERD status. This idea is consistent with rat reflux esophagitis model experiments that have shown esophageal tissue damage 41 and inflammation 42 to be more severe in males compared with females.
Health care-seeking behaviors also may explain some of the observations in the current study. Women have reported significantly higher symptom severity scores for heartburn and regurgitation compared with men of the same GERD stage, 34 which could suggest that women would seek more medical attention, receive more thorough medical workup, and have more opportunity for diagnosis of the components of MetS compared with men. Although if the perceived sex difference is attributed to increased health care use by women, then it is possible that men with MetS also are at an increased risk of EA, regardless of GERD status.
The main result from the current study demonstrating a positive association between MetS and EA is consistent with what to our knowledge is the only prior study to assess this hypothesis. 19 However, this prior study did not present results stratified by GERD status. In addition to demonstrating that MetS increases the risk of EA, it also is of interest to the field whether the association is driven by increasing the risk of the precursor lesion, BE, or by increasing the risk of BE progression to cancer. To the best of our knowledge, no studies to date have directly addressed the issue; however, a review hypothesized that MetS may be a risk factor for carcinogenic progression of BE. 6 Although we were unable to directly assess such a hypothesis, we did evaluate the association between MetS and EA compared with BE controls and found no association. BE tissue is known to express an array of proinflammatory cytokines, including IL-6, 24 IL-8, 22 IL-1b, and IL-10. 21 Furthermore, the severity of BE dysplasia also is associated with greater expression of proinflammatory cytokines including the transcription factor NF-rB. 22 Given the proinflammatory microenvironment that typifies BE, it appears to be unlikely that systemic inflammation, represented by MetS, could increase the risk of EA further. Indeed, the results of the current study support a mechanism by which MetS increases the risk of EA, possibly through increasing the risk of BE 15 and not by increasing the carcinogenic progression of BE.
Although the SEER-Medicare data enabled us to conduct a large study with which to test our hypotheses, several limitations inherent to the data constrained the interpretation and generalizability of the current study results. The findings are restricted to US adults aged 67.5 years. Our definition of MetS relied on medical billing, which insufficiently captured several exposure conditions, thus underestimating the number of patients exposed to MetS in this population. We also observed a low prevalence of obesity and smoking; however, capture efficiency is unlikely to differ by group and therefore should not bias the results of the current study. Due to the low sensitivity of GERD symptoms for acid reflux, misclassification could have occurred but this would usually bias results toward the null. In addition, GERD symptoms are highly specific and have been shown to correlate with the severity of exposure. 43 The strengths of the current study include the population-based ascertainment of cancer cases from cancer registries and Medicare beneficiaries randomly selected from within SEER cancer registry catchment areas. We were able to evaluate the presence of MetS before the diagnosis of EA. The population in the current study also was large enough to allow for analysis stratified by GERD and sex.
Using administrative data, a cost-effective approach with which to study risk factors of cancer, the current study is to our knowledge the first to demonstrate that MetS is associated with an increased risk of EA in men in the absence of GERD and women regardless of GERD status in an older population. We propose that the systemic inflammation conferred by MetS increases the risk of EA primarily by increasing the risk of the precursor lesion BE. Future studies should evaluate whether treating the conditions of MetS decreases risk of BE and EA. 
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